Get 20% Off Journals at LWW.com

Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation.

Blood 2019 02 20;133(8):867-877. Epub 2018 Dec 20.

Division of Hematology Oncology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL.

Cytomegalovirus (CMV) is the most common viral infection in hematopoietic cell transplantation (HCT) recipients. We performed deep phenotyping of CMV-specific T cells to predict CMV outcomes following allogeneic HCT. By using 13-color flow cytometry, we studied ex vivo CD8 T-cell cytokine production in response to CMV-pp65 peptides in 3 clinically distinct subgroups of CMV-seropositive HCT patients: (1) (n = 19): did not have evidence of CMV DNAemia on surveillance testing; (2) (n = 16): spontaneously resolved low-grade CMV DNAemia without antiviral therapy; and (3) (NC; n = 21): experienced clinically significant CMV. Two CMV-specific CD8 T-cell functional subsets were strongly associated with risk of CMV: (i) the (NPS; IL-2IFN-γTNF-αMIP-1β), found at increased levels among NC; and (ii) the (PS; IL-2IFN-γTNF-αMIP-1β) found at low levels among NC. High levels of the NPS and low levels of PS were associated with an increased 100-day cumulative incidence of clinically significant CMV infection (35% vs 5%; = .02; and 40% vs 12%; = .05, respectively). The highest predictive value was observed when these signatures were combined into a composite biomarker consisting of low levels of the PS and high levels of the NPS (67% vs 10%; < .001). After adjusting for steroid use or donor type, this composite biomarker remained associated with a fivefold increase in the risk of clinically significant CMV infection. CMV-specific CD8 T-cell cytokine signatures with robust predictive value for risk of CMV reactivation should prove useful in guiding clinical decision making in HCT recipients.

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-10-878918DOI Listing
February 2019
Save 15% Survey

Similar Publications

Humoral and cellular immunogenicity and safety following a booster dose of a tetravalent dengue vaccine 5+ years after completion of the primary series in Singapore: 2-year follow-up of a randomized phase II, placebo-controlled trial.

Hum Vaccin Immunother 2021 Feb 24:1-10. Epub 2021 Feb 24.

Research and External Innovation Department, Sanofi Pasteur, Marcy l'Etoile, France.

The tetravalent dengue vaccine (CYD-TDV) is approved for use as a 3-dose series for the prevention of dengue in seropositive individuals ≥9 years. A randomized, placebo-controlled, phase II study of a booster dose of CYD-TDV in individuals who completed the 3-dose schedule >5 years previously (NCT02824198), demonstrated that a booster restored neutralizing antibody titers to post-dose three levels. We present additional immunogenicity assessments up to 24 months post-booster, and B- and T-cell responses in a participant subset. Read More

View Article and Full-Text PDF
February 2021

Enhancing the immunogenicity of cancer vaccines by harnessing CLEC9A.

Hum Vaccin Immunother 2021 Feb 24:1-5. Epub 2021 Feb 24.

Cancer Immunotherapies Laboratory, Mater Research Institute, University of Queensland, Translational Research Institute, Woolloongabba, Brisbane, Australia.

Dendritic cell (DC) vaccines are a safe and effective means of inducing tumor immune responses, however, a better understanding of DC biology is required in order to realize their full potential. Recent advances in DC biology have identified a crucial role for cDC1 in tumor immune responses, making this DC subset an attractive vaccine target. Human cDC1 exclusively express the C-type-lectin-like receptor, CLEC9A (DNGR-1) that plays an important role in cross-presentation, the process by which effective CD8 T cell responses are generated. Read More

View Article and Full-Text PDF
February 2021

Neem leaf glycoprotein salvages T cell functions from Myeloid-derived suppressor cells-suppression by altering IL-10/STAT3 axis in melanoma tumor microenvironment.

Melanoma Res 2021 Feb 18. Epub 2021 Feb 18.

Department of Immunoregulation and Immunodiagnostics Department of Clinical Biochemistry, Chittaranjan National Cancer Institute Department of Botany, Ramakrishna Mission Vivekananda Centenary College, Rahara, Kolkata, India.

Myeloid-derived suppressor cells (MDSCs) suppress antitumor immune functions. We have observed that an immunomodulator, neem leaf glycoprotein (NLGP), inhibits tumor-resident MDSCs and enhances antitumor CD8+ T cell immunity. NLGP inhibits the number as well as functions of tumor-resident MDSCs (Gr1±CD11b±) and enhances antitumor CD8± T cell immunity by downregulating arginase 1 and inducible nitric oxide synthase production in MDSCs. Read More

View Article and Full-Text PDF
February 2021

Limited diversity in the CD8+ antigen-coding loci in Theileria parva parasites from cattle from southern and eastern Africa.

Vet Parasitol 2021 Feb 5;291:109371. Epub 2021 Feb 5.

Vectors and Vector-borne Diseases Research Programme, Department of Veterinary Tropical Diseases, Faculty of Veterinary Science, University of Pretoria, Private Bag X04, Onderstepoort, South Africa.

Theileria parva infections in cattle causes huge economic losses in the affected African countries, directly impacting the livelihood of the poor small-holder farmers. The current immunization protocol using live sporozoites in eastern Africa, is among the control measures designed to limit T. parva infections in cattle. Read More

View Article and Full-Text PDF
February 2021

Network models of primary melanoma microenvironments identify key melanoma regulators underlying prognosis.

Nat Commun 2021 02 22;12(1):1214. Epub 2021 Feb 22.

Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, USA.

Melanoma is the most lethal skin malignancy, driven by genetic and epigenetic alterations in the complex tumour microenvironment. While large-scale molecular profiling of melanoma has identified molecular signatures associated with melanoma progression, comprehensive systems-level modeling remains elusive. This study builds up predictive gene network models of molecular alterations in primary melanoma by integrating large-scale bulk-based multi-omic and single-cell transcriptomic data. Read More

View Article and Full-Text PDF
February 2021